AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

Deutsche Bank analyst David Hoang raised the firm’s price target on Sarepta (SRPT) to $12 from $6 and keeps a Sell rating on the shares. After ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...

Sarepta stock has been in free fall since safety issues derailed Elevidys, a gene therapy analysts had expected to achieve ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...